Compare MTC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTC | PRLD |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.8M | 69.1M |
| IPO Year | 2018 | 2020 |
| Metric | MTC | PRLD |
|---|---|---|
| Price | $5.33 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 29.7K | ★ 318.9K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $0.25 | $0.61 |
| 52 Week High | $5.49 | $4.19 |
| Indicator | MTC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 60.16 |
| Support Level | $0.84 | $0.99 |
| Resistance Level | N/A | $4.19 |
| Average True Range (ATR) | 0.40 | 0.36 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 88.06 | 54.79 |
MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.